Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women

Osteoporosis, Postmenopausal Clinical Trial

Official title:

Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women：A Randomized, Double-blind, Placebo-controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05402852
• Other study ID #: HT-PD-2021-08
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: June 1, 2022
• Est. completion date: December 31, 2023

Study information

• Verified date: May 2022
• Source: Shandong University
• Contact: Wei Zhao
• Phone: +8653188383308
• Email: zhao4wei2[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

EuBone is prepared by mixing eucommia ulmoides extract, fructus ulmoides extract and dodder extract in proportion. The aim of this study is to evaluate the effectiveness and safety of EuBone® capsules in slowing bone loss, preventing bone loss, and improving quality of life compared with placebo in Postmenopausal women.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 31, 2023
• Est. primary completion date: October 31, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

• Voluntarily sign written informed consent and comply with the requirements and restrictions of the test;
• Female subjects;Age: 45-75 years (including boundary values);Menopause =12 months;Not receiving hormone replacement therapy;
• Meet the bone reduction criteria: -2.5<T value<-1.0;
• OSTA index < -1, OSTA index = [body weight (kg) - age (years)] ×0.2;
• Have the ability of independent activities?

Exclusion Criteria:

• Patients with abnormalities in lumbar vertebra, hip bone and femoral neck cannot be measured by BMD;
• Patients with osteoporosis, BMD T-score of the whole hip, femoral neck or lumbar spine =-2.5;
• Have the following diseases known to affect calcium or bone metabolism: various metabolic bone diseases, such as osteogenesis imperfecta, osteomalacia; Paget's disease of bone; Cushing's syndrome; Hyperprolactitinemia; Hypopituitarism; Acromegaly; Rheumatoid arthritis; History of hyperparathyroidism or hypoparathyroidism;
• Patients who are suffering from or have suffered from osteomyelitis or osteonecrosis of the jaw, or who plan to undergo invasive dental surgery or jaw surgery during the trial, or who have unhealed dental or oral surgery wounds;
• Fractures in the past 6 months;
• People with allergic constitution, or known allergy to the test drug ingredients, or a history of allergy to any drug, food or pollen;
• Randomized prior or plan to use drugs that may affect bone turnover during the study period, including, but not limited to, the following: Used denumab , bisphosphonate or fluoride in the last 12 months, used Contraceptive pills containing estrogen, hormone replacement therapy (e.g., Tibolone, estrogen and selective estrogen receptor modulators, etc.), aromatase inhibitors, calcitonin, strontium salt, parathyroid hormone (or derivative), vitamin D supplements (> 1000 IU/ day), anabolic steroids, systemic glucocorticoids, calcitriol or analogues, diuretics, anticonvulsants in the last 6 months; Use inhaled or topical glucocorticoid drugs within 2 weeks;
• Had significant changes in physical activity within 6 months prior to randomization, or had been engaged in vigorous physical exercise, or planned to participate in vigorous physical exercise during the trial;
• Hepatitis B virus surface antigen (HBsAg), anti-hepatitis C virus antibody (HCV-AB), anti-HIV and anti-treponema pallidum antibody (TP-AB) are positive;
• Hypocalcemia or hypercalcemia, or serum albumin-corrected serum calcium levels not within the laboratory normal range;
• After inquiry, the average daily smoking quantity within 3 months prior to randomization =5, or can not stop smoking during the trial period;
• Binge drinking or drinking more than 28 units of alcohol per week (1 unit =350ml beer or 45ml spirits or 150ml wine) within 3 months prior to randomization;
• Have a history of drug abuse or drug abuse;
• Complete blood donation, component blood donation, or massive bleeding (>400 ml) within 3 months prior to randomization;
• Participants in interventional clinical trials of other drugs or devices within 3 months prior to randomization;
• Suffering from other important primary diseases (such as diseases of the nervous system, cardiovascular system, urinary system, digestive system, respiratory system or metabolic endocrine system) that are not considered suitable for admission, or for other reasons that are not considered suitable for admission;
• Other factors that the researcher considers unsuitable for inclusion.

Related Conditions & MeSH terms

• Osteoporosis
• Osteoporosis, Postmenopausal

Intervention

Drug:
• EuBone ® capsule
Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
• placebo
Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.

Locations

Country	Name	City	State
China	Shandong Provincial Qianfoshan Hospital	Ji'nan	Shandong

Sponsors (4)

Lead Sponsor	Collaborator
Shandong University	Chenland Nutritionals lnc., Jinan Hetai Pharmaceutical Technology Co., LTD, Shandong Provincial Qianfoshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The response rate of Quality of life score from baseline	To evaluate the improvement rate of the Quality of life score from baseline improvement rate	on day 360 after administration
Primary	The change of lumbar vertebra bone density	To evaluate the change of lumbar vertebra bone density from baseline	on day 360 after administration
Primary	The incidence rate of adverse events	To evaluate the incidence rate of adverse events	Through study completion, an average of 360 days
Secondary	The response rate of quality of life score	To evaluate the improvement rate of quality of life score from baseline	at 30, 90 and 180 days after administration
Secondary	The change of bone mineral density (BMD) at the total hip joint and femoral neck of the subject	To evaluate the change of bone mineral density (BMD) at the total hip joint and femoral neck of the subject after continuous administration of EuBone® capsule compared from baseline	at 180 and 360 days after continuous administration of EuBone® capsule
Secondary	The change of bone mineral density of lumbar vertebra (L1~L4)	To evaluate the change of bone mineral density of lumbar vertebra (L1~L4) after continuous administration of EuBone® capsule	at 180 after continuous administration of EuBone® capsule
Secondary	The change of serum n-terminal propeptide (S-PINP) and carboxy-terminal cross-linked peptide of type I procollagen (S-CTX) from baseline	To evaluate the change of serum n-terminal propeptide (S-PINP) and carboxy-terminal cross-linked peptide of type I procollagen (S-CTX) in EuBone® capsule from baseline	at 30, 90, 180 and 360 days after administration
Secondary	The change of parathyroid hormone (PTH), calcitonin (CT) and estrogen levels	To evaluate the changes of parathyroid hormone (PTH), calcitonin (CT) and estrogen levels after continuous treatment with EuBone® capsule from baseline	at 30, 90, 180 and 360 days after administration